Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| 0.6525 | |
| 0.6559 | |
| - | |
| 0.6726 | |
| 0.632 | |
| 0.52-3.33 | |
| 71 308 K | |
| 109 M | |
| 15 643 K | |
| -0.34 | |
| 0.504 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
A company’s size does not necessarily dictate the size of it’s returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that w...
Gritstone bio, Inc. (NASDAQ:GRTS) shareholders will doubtless be very grateful to see the share price up 52% in the last month. But the last three years have seen a terrible decline. To wit, the share...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
